methenolone enanthate 100mg/ml
- Home
- methenolone enanthate 100mg/ml
Description
INJECTABLE SOLUTION
intramuscularly
FORMULA
Each 1 ml ampoule contains:
Methenolone Enanthate………….100 mg
Excipients ………………. (s)
MECHANISM OF ACTION
Anabolic androgens are testosterone-derived steroids that attempt to chemically diminish androgenic and virilizing effects and increase anabolic actions. According to their chemical structure and function, they are divided into three groups. The second group is dihydrotestosterone (DHT) and derivatives, methenolone. Testosterone and androgens easily cross the cell membrane and bind to specific intracellular receptors, which have been purified and are proteins with a molecular weight of approximately 120 kilodaltons. Its synthesis is genetically determined on the X chromosome. DHT binds to a receptor site near a terminal carboxyl group. The steroid receptor complex is activated and is transported to the nucleus of the cell and binds to a receptor site on the DNA. increasing RNA polymerase activity and messenger RNA formation by stimulating the synthesis of cellular proteins responsible for physiopharmacological actions.
Informative
We emphasize that no one should consume without prior medical authorization.
Attention the therapeutic information of this product (treatment, prevention or indications for use) are not allowed in Brazil The therapeutic information present in the article is only valid in its country of origin usa.
They are pharmacologically active intramuscularly, testosterone is introduced by simple diffusion into daily cells due to its liposolubility, in many target tissues it is enzymatically converted into DHT by the action of an enzyme called t5-alpha-reductase, it is more active than testosterone. Biotransformation takes place in the liver, the main metabolites are eliminated in the urine. Peak concentrations are reached 6-11 days after the given injection. The absolute bioavailability of methenolone enanthate is 100%.
As for methenolone acetate, it is the oral form and is a derivative of DHT and has a mechanism similar to all anabolic androgenic steroids. It is metabolized in the liver and the elimination half-life is detected in the urine for up to 5 days after a single administration and the duration is approximately 24 hours.
INDICATIONS
It is indicated in states that require increased protein synthesis to improve the general condition of the patient or to prevent damage caused by catabolic processes, such as debilitating diseases, cachexia, advanced breast carcinoma or postmenopausal osteoporosis.
POSOLOGY
The intramuscular dose is 100 mg every 1 to 2 weeks or 200 mg every 2 to 3 weeks. day) is required. In women, the dose is 50-75 mg per day.
CONTRAINDICATIONS
Hypersensitivity to methenolone. Concomitant use with oral anticoagulants. It is contraindicated in patients with breast cancer (male), diagnosed or suspected prostate cancer or adenoma, heart, liver or severe kidney failure, in pre-pubescent or aggressive individuals, in pregnancy, active hypercalcemia.
ADVERSE EFFECTS
The following reactions require medical supervision: Virilization and menstrual irregularities in women, bladder irritability, gynaecomastia. Anaphylaxis, edema, erythrocytosis, gastrointestinal irritation, hypercalcemia and polycythemia, androgenic alopecia, seborrhea and acne in men and women. Carcinoma, prostatic hypertrophy and priapism, testicular atrophy, oligospermia, gynecomastia, sexual impotence, decreased libido: in women, hirsutism, acne, hoarseness, clitoral hypertrophy, mammary and endometrial atrophy, dysmenorrhea, cholestatic jaundice, excitability, hypercholesterolemia, hypercalcemia, edema . Adverse reactions of rare incidence during long-term or high-dose therapy are hepatic necrosis, leukopenia, hepatic purpura. Other adverse reactions are: constipation, nausea,
INTERACTIONS
Concomitant use with oral anticoagulants requires monitoring and adjustment of the anticoagulant dose. Co-administration with bupropion lowers the threshold of detection of systemic steroids. Oral antidiabetic or insulin requirements may be modified.
PRECAUTIONS AND WARNINGS
In the palliative treatment of breast cancer, do not continue the therapy if after 3 months the disease persists or if hypercalcemia is verified in any phase of the same. Serum and urinary calcium levels should be determined frequently in women with metastatic breast cancer under testosterone treatment. It is generally preferable to start treatment with full doses and then adjust to individual characteristics. Special care must be taken in patients with heart failure, arterial hypertension, renal failure, epilepsy, migraine, diabetes, bone metastases, dysmenorrhea, dyslipidemia, coagulation disorders, porphyria. Oral Methenolone Acetate should be taken on an empty stomach because food may decrease absorption.
USE RESTRICTIONS
professional use
OVERDOSAGE
Frequent doses can trigger symptoms of slow remission, as it is a long-acting medication. Immediate discontinuation of the medication is recommended. In case of overdose, consult your doctor or go to the Toxicology Center of the Emergency Center.
PRESENTATION
Methenolone Enanthate 100 mg. Injectable:
Box containing 1 vial of 10ml
Store at a temperature below 25°C in a dry place and out of the reach of children.